Skip to main content
. 2004 Dec;78(24):14039–14042. doi: 10.1128/JVI.78.24.14039-14042.2004

FIG. 2.

FIG. 2.

Recombinant viral assay to determine the sensitivity of patient-derived virus to the MAbs 2F5, 2G12, and 4E10. (A) Patient sample demonstrating susceptibility to all three MAbs: 2F5 (IC50, 1.74 μg/ml), 2G12 (IC50, 4.32 μg/ml), and 4E10 (IC50, 1.88 μg/ml). (B) Patient sample susceptible to both 2F5 (IC50, 6.49 μg/ml) and 4E10 (IC50, 5.88 μg/ml) but not to 2G12 (IC50, >50 μg/ml). (C) Susceptibility to 4E10 is preserved (IC50, 8.87 μg/ml) in the face of resistance to both 2G12 (IC50, >50 μg/ml) and 2F5 (IC50, >50 μg/ml).